Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
GlaxoSmithKline
Eli Lilly and Company
Accent Therapeutics
A2 Biotherapeutics Inc.
Revolution Medicines, Inc.
GlaxoSmithKline
Natera, Inc.
Novartis
Massive Bio, Inc.
Elicio Therapeutics
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Tempus AI
Taproot Health
DxTerity Diagnostics
UTC Therapeutics Inc.
Corvus Pharmaceuticals, Inc.
Klus Pharma Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
MacroGenics
Stryker Orthopaedics
SpeciCare
SPGO Research Mannheim GmbH
INSYS Therapeutics Inc
Siemens Molecular Imaging
Light Sciences LLC